

Contents

ABOUT THE EDITORS — v

HISTORICAL DEVELOPMENT
AND PERSPECTIVES OF THE SERIES — vii

PREFACE TO VOLUME 19 — ix

CONTRIBUTORS TO VOLUME 19 — xix

TITLES OF VOLUMES 1–44 IN THE
METAL IONS IN BIOLOGICAL SYSTEMS SERIES — xxiii

CONTENTS OF VOLUMES IN THE
METAL IONS IN LIFE SCIENCES SERIES — xxv

Peggy L. Carver

1 METALS IN MEDICINE: THE THERAPEUTIC USE OF METAL IONS IN THE CLINIC — 1

Abstract — 2

1. Introduction — 2
2. Metal-Related Diseases — 4
3. Metals as Medicines — 5
4. Metal Ion Toxicology — 10
5. Concluding Remarks — 11

Abbreviations — 11

References — 11

Anne Robert, Françoise Benoit-Vical, Yan Liu, and Bernard Meunier

2 SMALL MOLECULES: THE PAST OR THE FUTURE IN DRUG INNOVATION? — 17

Abstract — 18

1. Introduction — 18
2. Brief Historical Overview of Chemical Drug Development — 19
3. Trioxaquinones: Antimalarial Hybrid Molecules with a Dual Mode of Action — 28

- 4. Regulation of Copper Homeostasis in Alzheimer's Disease — **34**
- 5. General Conclusions — **42**
- Acknowledgments — **42**
- Abbreviations and Definitions — **42**
- References — **42**

Guido Crisponi, Valeria M. Nurchi, and Joanna I. Lachowicz

- 3** IRON CHELATION FOR IRON OVERLOAD IN THALASSEMIA — **49**
- Abstract — **50**
- 1. Introduction — **50**
- 2. Overview on Thalassemias — **51**
- 3. Iron Chelation Therapy — **55**
- 4. Chelators in Use — **58**
- 5. Combination Therapy — **74**
- 6. New Chelators — **75**
- 7. Concluding Remarks — **79**
- Acknowledgments — **80**
- Abbreviations and Definitions — **80**
- References — **81**

Roberta J. Ward and Robert R. Crichton

- 4** IRONING OUT THE BRAIN — **87**
- Abstract — **88**
- 1. Iron Homeostasis in the Brain — **88**
- 2. Neurodegenerative Diseases, Disruption of Iron Homeostasis, and Iron Speciation — **101**
- 3. Iron and the Immune System — **108**
- 4. Iron Chelation Present and Future Directions — **112**
- 5. Concluding Remarks — **114**
- Abbreviations — **115**
- References — **117**

Manfred Nairz and Guenter Weiss

- 5** INFECTIONS ASSOCIATED WITH IRON ADMINISTRATION — **123**
- Abstract — **124**
- 1. Introduction — **124**
- 2. Iron, Immune Function, and Infection — **129**
- 3. Iron Administration and Infection — **135**
- 4. Concluding Remarks and Suggestions for Future Research — **143**
- Acknowledgments — **143**
- Abbreviations — **143**
- References — **145**

Amy Barton Pai

- 6** IRON OXIDE NANOPARTICLE FORMULATIONS FOR SUPPLEMENTATION — **157**
Abstract — **158**
1. Introduction — **158**
2. Structure and Biodistribution of Intravenous Iron Formulations — **159**
3. Therapeutic Efficacy in the Dialysis Population — **164**
4. Adverse Safety Signals — **167**
5. Concluding Remarks: Gaps in Regulatory Science for Intravenous Iron Formulations — **174**
Abbreviations — **176**
References — **176**

Elzbieta Gumienna-Kontecka and Peggy L. Carver

- 7** BUILDING A TROJAN HORSE: SIDEROPHORE-DRUG CONJUGATES FOR THE TREATMENT OF INFECTIOUS DISEASES — **181**
Abstract — **182**
1. Introduction — **182**
2. Overview of Siderophores — **183**
3. Siderophore Antimicrobial Conjugates — **191**
4. Use of Siderophore-Drug Conjugates to Alter the Spectrum of Activity of an Antimicrobial — **197**
5. Lessons Learned from the Development of Antibacterial Siderophore Drug Conjugates — **198**
6. Concluding Remarks — **199**
Acknowledgment — **200**
Abbreviations — **200**
References — **200**

Debbie C. Crans, LaRee Henry, Gabriel Cardiff, and Barry I. Posner

- 8** DEVELOPING VANADIUM AS AN ANTIDIABETIC OR ANTICANCER DRUG: A CLINICAL AND HISTORICAL PERSPECTIVE — **203**
Abstract — **204**
1. Introduction: Antidiabetic Vanadium-Containing Compounds — **204**
2. Biological Activities of Vanadium Compounds — **209**
3. Human Studies with Vanadium Compounds — **214**
4. Commercialization of Vanadium as Antidiabetic Agent — **219**
5. What is Next? — **221**
6. Conclusions and Outlook — **224**
Acknowledgment — **225**
Abbreviations — **225**
References — **225**

Wolfgang Maret

- 9 CHROMIUM SUPPLEMENTATION IN HUMAN HEALTH, METABOLIC SYNDROME, AND DIABETES — 231**
Abstract — **232**
1. The Nature of Essential Chemical Elements — **232**
 2. Chromium in Mammalian Biology — **235**
 3. Redox and Coordination Chemistry of Chromium Relevant to Biology — **237**
 4. Chromium Metabolism — **239**
 5. Low-Molecular-Weight Biological Chromium Complexes — **240**
 6. Chromium Toxicity — **241**
 7. Chromium in Diabetes and Metabolic Syndrome — **243**
 8. Possible Resolution of Controversies in Chromium Biology — **246**
- Acknowledgment — **248**
Abbreviations — **248**
References — **248**

Keith M. Erikson and Michael Aschner

- 10 MANGANESE: ITS ROLE IN DISEASE AND HEALTH — 253**
Abstract — **254**
1. Introduction — **254**
 2. Manganese Essentiality — **255**
 3. Factors Involved in Manganese Status — **257**
 4. Manganese Neurotoxicity — **260**
 5. Conclusions — **262**
- Acknowledgment — **262**
Abbreviations — **262**
References — **263**

Elizabeth A. Bajema, Kaleigh F. Roberts, and Thomas J. Meade

- 11 COBALT-SCHIFF BASE COMPLEXES: PRECLINICAL RESEARCH AND POTENTIAL THERAPEUTIC USES — 267**
Abstract — **268**
1. Introduction — **268**
 2. Antimicrobial Activity — **269**
 3. Antiviral Activity — **275**
 4. Anticancer Activity — **276**
 5. Inhibiting Aggregation of Amyloid- β — **284**
 6. Conclusions — **293**
- Acknowledgments — **294**
Abbreviations and Definitions — **294**
References — **295**

Jay Lopez, Divya Ramchandani, and Linda Vahdat

- 12 COPPER DEPLETION AS A THERAPEUTIC STRATEGY IN CANCER — 303**
Abstract — **304**
1. Introduction — **304**

2. Metals — **304**
 3. Copper Homeostasis in Pathophysiology — **307**
 4. Copper in Cancer — **309**
 5. Preclinical Studies — **314**
 6. Clinical Trials of Copper Depletion in Cancer — **318**
 7. Concluding Remarks and Future Directions — **320**
- Acknowledgments — **320**
Abbreviations — **321**
References — **322**

Dinorah Gambino and Lucía Otero

- 13** METAL COMPOUNDS IN THE DEVELOPMENT OF ANTIPARASITIC AGENTS: RATIONAL DESIGN FROM BASIC CHEMISTRY TO THE CLINIC — **331**
- Abstract — **332**
1. Introduction — **332**
 2. Rational Design of Prospective Agents — **337**
 3. Identification and Validation of Parasite Targets — **347**
 4. Metallomics in Parasites — **349**
 5. Preclinical Studies — **350**
 6. Concluding Remarks and Perspectives — **352**
- Acknowledgments — **353**
Abbreviations — **353**
References — **354**

Sigrídur G. Suman and Johanna M. Gretarsdóttir

- 14** CHEMICAL AND CLINICAL ASPECTS OF METAL-CONTAINING ANTIDOTES FOR POISONING BY CYANIDE — **359**
- Abstract — **360**
1. Introduction — **360**
 2. Naturally Occurring Cyanide — **362**
 3. Poisoning by Cyanide — **367**
 4. Metal-Containing Antidotes — **372**
 5. Concluding Remarks — **385**
- Acknowledgment — **386**
Abbreviations and Definitions — **386**
References — **386**

SUBJECT INDEX — **393**

